Sunvozertinib Drug Asset Due Diligence Report 2026

This Sunvozertinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

170

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Sunvozertinib can convert its Small molecule drug profile and EGFR exon 20 x HER2 exon 20 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Sunvozertinib (query alias: Sunvozertinib)
Modality / target	Small molecule drug; EGFR exon 20 x HER2 exon 20; EGFR exon 20 inhibitors, HER2 exon 20 inhibitors
Highest global status	Approved
Originator	Dizal Pharmaceutical Co., Ltd.
Active developers	Dizal Pharmaceutical Co., Ltd.

The MCP disease footprint includes EGFR ex20ins mutation in non-small cell lung cancer, Non-small cell lung cancer stage I, Non-small cell lung cancer stage IIIA. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07182682	Phase 3	Recruiting	360	Disease-free survival (DFS) by investigator assessment
NCT07117890	Phase 2	Recruiting	34	Objective Response Rate(ORR)
NCT07274761	Phase 2	Active, not recruiting	24	Objective response rate (ORR)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).

Phase 3; n=324; evaluation: Positive. Reported fields: mPFS = 7.5 month ; mPFS = 10.3 month

First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion Mutations

Phase 3; n=324; evaluation: Positive. Reported fields: AE(Grade 3 or higher) = 56.7 % ; AE(Grade 3 or higher) = 75.5 %

44P - Sunvozertinib showed profound antitumor activities as first-line treatment in advanced NSCLC patients harboring P-loop and alpha C-helix compressing (PACC) or other uncommon mutations

Phase 2; n=39; evaluation: Positive. Reported fields: DCR = 100.0 % ; DCR = 78.3 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Sunvozertinib addresses EGFR ex20ins mutation in non-small cell lung cancer, Non-small cell lung cancer stage I, Non-small cell lung cancer stage IIIA. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 170 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: EGFR exon 20 x HER2 exon 20 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-05-18	全面强化肺癌治疗版图！复宏汉霖引进正大丰海/江苏创特三代口服EGFR-TKI	NDA/BLA	Financial terms not disclosed
2026-02-26	Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics	Preclinical	Financial terms not disclosed
2025-12-17	Glenmark enters collaboration and distribution agreement with Jiangsu Hansoh Pharma for Aumolertinib, a third-generation GFR-TKI to treat NSCLC	Approved	US$1,000.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO